Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LEAT - Great quarter, and it is the next quarter that is the largest quarter. I don't think there has been any slowdown, and I think at first the distributors weren't taking as much new product, whereas that has now changed. They also talked about ecommerce being a large contributor. So the next quarter will probably be significant. In their press release from the previous quarter they had previously downplayed results not expecting much from this quarter. They were very upbeat on the conference call. They seemed almost disappointed that there was only one question.
SCIA 10Q from 8/7
Net Income down to zero.
"Thus, we expect revenue to be lower in the second half of 2020 compared to the first six months of this year."
https://www.otcmarkets.com/filing/html?id=14318113&guid=OOR6UH20MGpAhZh
Press Release is out, they do sound optimistic on next quarter, and that they will get new contract wins and orders that they can put into their backlog.
https://www.otcmarkets.com/stock/OPXS/news/Optex-Systems-Holdings-Inc-Announces-Third-Quarter-of-Fiscal-Year-2020-Financial-Highlights?id=270487
OPXS 10q out
Looks like the warrants obscured the numbers again and made it look like a loss. EBITDA doubled, but it seems like it was all due to higher gold prices for redemptions on gold they use on the lenses. So seems flat in actuality.
https://www.otcmarkets.com/filing/html?id=14325576&guid=K1R6UKC9-DOqE3h
LEAT 3.55 getting some love
ZYXI has been on a tear even despite that short attack article.
OPXS nice buys on OPXS. Announced they are now buying back shares.
I still use Yahoo even though they have pretty much destroyed all the usefulness of it. Recently I noticed that the earnings stopped showing up. I already have to go elsewhere to get the news since they cut the old stories off after the headline.
ZYXI is doing great. And now is being awarded a PE of 63 for their great performance. Meanwhile they are growing revenues at 66% and still accelerating. Very interesting setup.
SMSI results out, look pretty good. 57% rev growth. .10 nongaap .03 gaap versus .00 last year. "Immense opportunities everywhere we look" - from conference call. Rev guidance in Q2 down 4-9% due to COVID
https://www.otcmarkets.com/stock/SMSI/news/story?e&id=1595104
SCIA seemed to have nothing special in their report.
ZYXI ($16.40 AH) another great quarter
Revenues up 66%
Orders up 126%
Guidance for 70% to 75% rev growth.
Hiring pace now at 48 reps a month
Halfway done with a new model of bood volume monitor
https://www.otcmarkets.com/stock/ZYXI/news/story?e&id=1587006
He said something to suggest that the new wins will be potentially larger than anything they have done in 2019. Not sure if the 4 that got pushed are of the larger variety or not. He also said the larger deals will take a longer engagement. So that might suggest that these 4 are bigger deals since they are taking longer.
11 customer wins this quarter versus 8 wins last quarter
ZYXI is recovering nicely
SMSI - I thought it was against your rules to hold stocks through earnings. I mean I bought some at $5.60 today also because I thought the results would be good, and I thought the call was great, but I thought you always traded the expectations. Anyway, I hope it goes to the moon tomorrow, but I'm not sure because this stock sells off fairly easily.
ZYXI (13.30 +11% in after hours) had another great quarter. 52% revenue growth yoy, 30% increase in EBITDA yoy. Full year revenue estimate is approximately 65% to 76% above 2019 revenue. The blood volume monitor was FDA approved last year. Hired 40 reps since the beginning of the year.
http://zynexmed.investorroom.com/2020-02-27-Zynex-Announces-2019-Fourth-Quarter-and-Full-Year-Earnings
OBCI is this getting roped into the Corona virus story?
Zynex Announces 2019 Fourth Quarter and Full Year Earnings
ENGLEWOOD, Colo., Feb. 27, 2020 /PRNewswire/ --
2019 Full Year
Revenue increased 42% year over year to $45.5 million
Net income $9.5 million; Diluted EPS $0.28
2019 Revenue, net income and Adjusted EBITDA are the highest in Company history
Adjusted EBITDA increased 11% to $12.1M
2019 Fourth Quarter
Revenue increased 52% year over year to $14.2 million
Orders increased 129%
Net income of $2.9 million; Diluted EPS $0.09
Adjusted EBITDA increased 30% to $4.1 million
Fourteenth consecutive quarter of positive net income
Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported financial results for its fourth quarter and full year ended December 31, 2019.
Zynex
Fourth Quarter Financial Results Summary:
For the fourth quarter, the Company reported net revenue of $14.2 million, a 52% increase over the fourth quarter of 2018. Gross margins were 80% in the fourth quarter of 2019 and net income was $2.9 million.
Adjusted EBITDA was $4.1 million in the fourth quarter of 2019.
The Company generated $2.1 million of cash from operations during the fourth quarter of 2019. As of December 31, 2019, the Company had working capital of $17.4 million a 137% increase compared to $7.3 million at December 31, 2018. Cash on hand was $14.0 million at the end of the fourth quarter.
President and CEO Commentary:
Thomas Sandgaard, CEO said: "In the fourth quarter, we posted revenue of $14.2 million, which is the highest quarterly revenue in the history of the Company and net income of $2.9 million. Orders grew 129% compared to the fourth quarter of 2018 up from 95% year-over-year growth in the third quarter.
"In the fourth quarter, we continued to focus on the execution of our growth strategy and the related growth of our sales force. We expect the addition of new sales reps to have an impact on order and revenue growth this year and going forward. In addition, we continue to invest in our infrastructure to support the increase in order volume.
"We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."
First Quarter and Full Year 2020 Guidance:
The estimate range for the first quarter revenue is between $14.0 and $14.5 million with Adjusted EBITDA between $2.3 and $2.8 million as we continue to invest in growing our sales force. The revenue estimate is approximately 52% to 58% above 2019 first quarter revenue of $9.2 million. First quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year.
Full year 2020 revenue is estimated between $75.0 and $80.0 million with Adjusted EBITDA between $15.0 and $18.0 million. The full year revenue estimate is approximately 65% to 76% above 2019 revenue of $45.5 million.
Conference Call and Webcast Details:
Thursday, February 27, 2020 at 2:15 p.m. MT – 4:15 p.m. ET
To register and participate in the webcast, interested parties should click on the following link or dial in approximately 10-15 minutes prior to the webcast:
https://www.webcaster4.com/Webcast/Page/1487/33247
US PARTICIPANT DIAL IN (TOLL FREE):
1-844-825-9790
INTERNATIONAL DIAL IN:
1-412-317-5170
Canada Toll Free:
1-855-669-9657
I also thought the FDA approval would drive the stock much higher on the news, but the market seems to be shrugging it off. I'm looking forward to tomorrow's earnings and guidance for next quarter.
SEAC I also purchased some around $4. Company is trading at P/E of 10 or less annualized with one-times excluded. The contracts are basically a million upfront and then a million per year for four more years. So if they continue at the same sales rate they've been at the last quarter then revenue should double in a year. The CEO says they've invested $250 million recently in there development, albeit inefficiently, so they are a generation or two ahead of the competition. He says they have a new product that is already developed that they will roll out next year. So there is a chance that sales could accelerate. Cash flow has been a problem but CEO says they will be cash flow positive this quarter.
It looks like clearance of the cardiac monitor. I'm surprised the stock isn't up more on this.
SMDM put in an awful quarter with .76M loss.
https://www.otcmarkets.com/stock/SMDM/news/Singing-Machine-Announces-Third-Quarter-2020-Earnings-Report?id=253887
Thanks, does that mean he exercised some stock options and now owns common stock?
PDEX might be fairly valued on a trailing basis, but I think the larger opportunity is in their self-branded products they have in development which could be huge, but will take some time to play out.
Thoracic Driver
Arthroscopic Shaver (1)
ENT Shaver
Arthroscopic Attachment
CMF Driver
SEAC there were some recent insider sales
https://www.otcmarkets.com/stock/SEAC/disclosure
I don't think the blood volume monitor is priced in. I would say it is a buy the news event.
ZYXI gets European patent on blood volume monitor. FDA and CE marking must be coming soon.
https://finance.yahoo.com/news/zynex-obtains-european-patent-blood-142000568.html
ITCC - was there a promo on this one?
I own this. They have some huge government deals, but they aren't allowed to say much about them. The proof will have to come from earnings, or a buyout.
I have a FRAN position. They have been closing unprofitable stores and the CEO seems to have a clear, reasonable picture of what he wants to do. Hopefully there are no unanticipated costs associated with closing these stores, but they have already closed some of them, and returned to profitability. In the last quarter they were heavily discounting items that weren't selling to get rid of the excess inventory. Now with those gone hopefully the new batch have been selling with higher margins.
OPXS announces a shared award. Backlog is down to $23.6M versus the $25M they announced Nov 12. I hope that is because they are working through it. Not sure what value they are assigning to this in the backlog since it is said that the exact number of units is yet to be determined.
Optex Systems Holdings, Inc. Announces a Shared $35 Million Award from Defense Logistics Agency
ACCESSWIRE ACCESSWIREDecember 3, 2019
RICHARDSON, TX / ACCESSWIRE / December 3, 2019 / Optex Systems Holdings, Inc. (OPXS), a leading manufacturer of precision optical sighting systems for domestic and worldwide military and commercial applications, announces a shared award for a maximum of $35 Million for Improved Commander Weapon System (ICWS) periscopes under a three year Indefinite Delivery - Indefinite Quantity (IDIQ) contract with two additional optional years.
Optex and another recipient have been awarded this shared award from Defense Logistics Agency, Land and Maritime. Each company's portion of the award will depend on price and performance over the ordering periods. Both companies have produced the product in the past and both companies are currently in production under different contracts.
Danny Schoening, CEO of Optex commented, "While the exact number of units to be ordered is yet to be determined, we know this item is critical to the continued production and support of the M1A2 Abrams Tank. Given this demand and this approved IDIQ contract, Optex is ready to react to the Government's needs for this mission critical periscope."
With this order, Optex's current backlog stands at over $23.6 Million.
TTLO - congrats on your purchase. And thanks for the alert though I did not buy any. Always impressed by how you make money in these companies that others don't have the stomache for.
I own XPEL. During the time period of this contest it was listed on the NASDAQ and enjoyed multiple expansion as it has also continued to execute well. They have had ~40% growth for a very long time and have continued to execute and move into international markets and produce new products. They still have a bright future, but the stock is not very cheap. They will probably be listed on the Russell 2000 in 2020, so I think they will stay strong in the next few months because of that and because they are executing well.
DGSE was a turnaround that took a few years and finally started working out. They are a chain of jewelry stores in Texas. During the past big gold move they started buying gold and were doing well with that until the the gold move ended and took their profits with it. So they started refocusing on the jewelry store business which lowered revenue temporarily as they exited the gold business. Now they are moving into the recommerce space, reselling used cellphones and other things, and it seems to be working out. There was some sort of acquisition/merger that started the recent run. I owned them during the turnaround but got out when I could because I got impatient that it was taking too long and the market didn't like the lower revenues, and I wasn't sure whether this recommerce initiative was going to work out.
I don't know anything about HEBT.
Congrats otcbargains. Thanks SKILLZ
It closed decisively above $9.39
Strong move above that level today. Not sure what is prompting all the buying today. Let's see if it holds.
From the call, the potential recovery from insurance is over $2Million. What they do not recover they will seek to recover from the vendor. It was a low-margin Black Friday product for Walmart that was damaged. It is difficult to get all information from Walmart to provide the insurers.
They will be impacted by tariffs going forward and have already paid tariffs of $200K. They aren't able to quickly and easily move their manufacturing out of China.
The China channel is open online but will take time to develop in stores.